Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Applied Biosystems
Study confirms value of TaqMan drug metabolism genotyping assays in complex disease research
November 7th, 2006
Scientists from Applied Biosystems (ABI), an Applera Corporation business, and SAIC-Frederick, Inc. presented data showing that the TaqMan drug metabolism genotyping assays provide higher accuracy than other methodologies in identifying variation in genes that code for drug metabolism enzymes. Identifying these variations is important in both drug development and clinical research as they are associated with certain diseases such as cancer and have been shown to significantly impact drug efficacy. Robert Welch, deputy director of the Core Genotyping Facility, a contractor operated facility run by SAIC-Frederick, Inc. for the National Cancer...
Source: Drug Law Weekly (2006-11-07)
|
